Compare Pfizer Inc (PFE) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Prospect Capital Corporation — how do they compare? Pfizer Inc trades at $27.87 (market cap $158.39B), while Prospect Capital Corporation trades at $2.2 (market cap $1.13B). The key difference: Pfizer Inc is far larger — about 140.2× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (19.09%). Which is the better fit depends on your goals.
| PFE | PSEC | |
|---|---|---|
Market Cap | $158.39B | $1.13B |
Volume | 29,869,932 | — |
Sector | Health | Financials |
52-Week High | $29.02 | $3.05 |
52-Week Low | $23.60 | $2.11 |
Enterprise Value | $209.89B | — |
Dividend Yield | 6.19% | 19.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
Prospect Capital (PSEC) trades at $2.19, down 1.79% recently, with a bearish technical signal and deep discount to book value (P/B 0.39). The company reported negative revenue and net income for 2025, though quarterly EPS has beaten estimates. It maintains a high dividend yield, paying $0.04 monthly, but faces net cash outflow and portfolio contraction concerns highlighted in recent news.
Outlook remains cautious due to financial deterioration and NAV erosion risks, offset by high yield and valuation discount. Analyst consensus is mixed with 25% buy ratings, reflecting divided opinion on recovery potential versus ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
